



**THE FOUNDATION
FOR SECURE
MARKETS®**

#55218

Date: September 19, 2024

Subject: GERM Options - Expiration Pricing Consideration

GERM (Amplify Treatments, Testing and Advancements ETF) options will be subject to special pricing consideration in expiration processing on September 20, 2024. The pricing consideration is due to the undetermined final cash amount included in the option deliverable of GERM as indicated below. These options will continue to be subject to normal exercise based on customary exercise thresholds in OCC's Ex-by-Ex processing.

MEMBERS SHOULD ADVISE THEIR CUSTOMERS TO TAKE THE FOLLOWING CONSIDERATIONS INTO ACCOUNT IN DECIDING TO EXERCISE, OR NOT TO EXERCISE, THESE OPTIONS.

GERM

GERM options are Amplify Treatments, Testing and Advancements ETF options, which were adjusted on September 11, 2024 (see OCC Information Memo #55177). The deliverable of GERM options is:

NEW DELIVERABLE

PER CONTRACT: 100 x the cash proceeds amount paid per GERM share, less any applicable transactions costs, pursuant to the liquidation.

As of September 19, 2024 the GERM Exchange Agent has not determined the final net cash amount applicable in the liquidation.

For purposes of calculating a GERM price for use in expiration processing, OCC will use the following formula:

$$\text{GERM} = 19.30$$

This formula only includes the first liquidating distribution and does not include any subsequent liquidating distribution amounts, if any.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.